by Madaline Spencer and James Radke, PhD | May 22, 2026
Pablo Villoslada, MD, PhD, Founder and Medical Director of Accure Therapeutics and Head of Pathogenesis and New Therapies MS at IDIBAPS in Hospital Clínic in Barcelona, discusses results from the ACUITY clinical trial testing privosegtor to treat patients with acute...
by Madaline Spencer | May 22, 2026
A recent publication in the Clinical Journal of the American Society of Nephrology presented outcomes of pegcetacoplan treatment in adolescents with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and IC-MPGN...
by Madaline Spencer | May 21, 2026
A recent clinical study analysis of Oxbryta (voxelotor), globally withdrawn in 2024, was submitted to the FDA with the intent of getting voxelotor back on the market. Sickle cell disease (SCD) is a disorder in which red blood cells become “sickle”-shaped and can not...
by Madaline Spencer | May 20, 2026
Hans Katzberg, MD, Professor of Neurology at the University of Toronto and Neurologist at Toronto General Hospital, discusses post hoc analyses from the ADHERE clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a...
by Madaline Spencer | May 19, 2026
Angela Zhu, MD, is an Ophthalmologist and Clinical Assistant Professor, Pediatric & Adult Cornea/Cataract/External Diseases, at Bascom Palmer Eye Institute in Miami. In this interview with CheckRare, Dr. Zhu describes some of the key features of plasminogen...
